ANI Pharmaceuticals Announces the Launch of Propafenone Tablets

ANI Pharmaceuticals, Inc. ("ANI")

today announced the launch of Propafenone Hydrochloride 150mg, 225mg and 300mg oral tablets, indicated for use in the treatment of various arrhythmias. The overall US market for Propafenone Hydrochloride 150mg, 225mg and 300mg tablets was $14 million in 2014, per IMS Health. Arthur S. Przybyl, President and Chief Executive Officer said, "We are pleased to announce the launch of our fourth product from the portfolio of approved generic products we acquired from Teva in January 2014."